JP4886107B2 - Oral dissolving tablets for periodontal disease prevention - Google Patents

Oral dissolving tablets for periodontal disease prevention Download PDF

Info

Publication number
JP4886107B2
JP4886107B2 JP2000313711A JP2000313711A JP4886107B2 JP 4886107 B2 JP4886107 B2 JP 4886107B2 JP 2000313711 A JP2000313711 A JP 2000313711A JP 2000313711 A JP2000313711 A JP 2000313711A JP 4886107 B2 JP4886107 B2 JP 4886107B2
Authority
JP
Japan
Prior art keywords
tablet
vitamin
periodontal disease
weight
hardness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000313711A
Other languages
Japanese (ja)
Other versions
JP2002121133A (en
Inventor
秀彦 大槻
幸代 関元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunstar Inc
Original Assignee
Sunstar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunstar Inc filed Critical Sunstar Inc
Priority to JP2000313711A priority Critical patent/JP4886107B2/en
Publication of JP2002121133A publication Critical patent/JP2002121133A/en
Application granted granted Critical
Publication of JP4886107B2 publication Critical patent/JP4886107B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【0001】
【発明の属する技術分野】
本発明は、歯周病の予防を目的とした口腔内溶解錠に関する。
【0002】
【従来の技術】
従来歯周病の予防目的で、抗菌や抗炎症効果等さまざまな切り口を有する天然物の提案がなされている。例えば特開平11−243910号公報には高溶解性カルシウムと油溶性カンゾウエキス、大豆イソフラボン、茶抽出物からなる抗菌性植物エキスとの組み合わせ、特開平11―302142号公報にはビタミンCやEと天然ポリフェノールとの組み合わせによる歯周病予防用組成物が開示されている。このような組成物を配合した食品剤形として、口腔内の局所的作用を期待する上で、口腔内で溶解させる錠剤が有用である。
【0003】
また、口腔内溶解錠は、口腔内で咀嚼、溶解させるための適度な硬度と口どけ時にざらつきが無く、かつ製造段階や物流段階で、欠け・割れ等の摩損が生じないことが必要である。しかしながら、歯周病予防のための有効成分であるビタミン、カルシウム成分を配合しかつその配合量が多くなると、通常、口腔内溶解錠で用いられる糖アルコールの種類によっては、錠剤の硬度がでなかったり、硬度がでても割れ、欠け等の摩損が大きく製造や物流段階での衝撃に耐えられないことが判明した。
【0004】
【発明が解決しようとする課題】
本発明は、適度な硬度で摩損性が低く、口どけ時にざらつきがなく使用感に優れた歯周病予防のための口腔内溶解錠を提供するものである。
【0005】
【課題を解決するための手段】
本発明者は、ビタミンC及びビタミンEあるいはカルシウム成分を有効成分とする歯周病予防口腔内溶解錠における、欠け、割れ等が生じず、口溶け等の使用感を向上させるべく鋭意検討した結果、意外にもある種の糖アルコールの組み合わせにより、上記課題を解決することができ、本発明を完成するに至った。
【0006】
すなわち、本発明は、
項1 ビタミンC及びビタミンEあるいはカルシウム成分を有効成分とし、且つパラチニット、マルチトール、ソルビトールからなる糖アルコールから選択される1種以上を配合することを特徴とする歯周病予防用口腔内溶解錠。
項2 さらに2糖以上の重合還元糖から選ばれる1種以上を配合することを特徴とする項1に記載の歯周病予防用口腔内溶解錠。
項3 ビタミンC及びビタミンEの合計量、あるいはカルシウム成分の配合量が25〜60重量%、糖アルコールの配合量が30〜60重量%であることを特徴とする項1、2の何れか1項に記載の歯周病予防用口腔内溶解錠。
項4 湿式造粒により調製した顆粒を打錠した錠剤であって、その錠剤硬度が5kg〜15kgである項1、2、3の何れか1項に記載の歯周病予防用口腔内溶解錠。
項5 さらに油溶性カンゾウ抽出物、大豆イソフラボン抽出物、茶抽出物、ぶどう種子抽出物からなる植物抽出物から選択する1種又は2種以上を配合することを特徴とする項1、2、3、4の何れか1項に記載の歯周病予防用口腔内溶解錠。
本発明において、「歯周病予防」とは、歯周病にならないように歯周病の発症を抑制、防止すること、歯周病になった場合にその進行を抑制し防止すること及び生活習慣や全身疾患あるいはある特定の全身の状態により、歯周病の進行や発症に影響を及ぼす歯周病のリスクを低減することを意味する。
【0007】
【発明の実施の形態】
本発明中に用いるビタミンCは、アスコルビン酸及びアスコルビン酸ナトリウム、アスコルビン酸カルシウムなどの塩があげられ、組成物中に25〜60重量%、好ましくは25〜40重量%配合することができる。
本発明に用いるビタミンEは、天然あるいは合成のビタミンE及びそれらとコハク酸、酢酸、ニコチン酸等のエステルなどのビタミンEを組成物中に0.1重量%〜10重量%、好ましくは0.5%〜5重量%配合することができる。
【0008】
また、ビタミンEにおいては粉末ビタミンE製剤の形態で用いるのが最も好ましい。粉末ビタミンE製剤は、例えばビタミンEをアラビアガム等で乳化し、デキストリンや乳糖などの粉末化基剤を加えてスプレードライする方法、あるいは二酸化ケイ素、デキストリン等の多孔質の粉体に吸着させる方法により製造できる。粉末ビタミンE製剤にはビタミンEが1〜50重量%含有され、ビタミンE製剤として組成物中に0.05〜40重量%配合することができる。これらビタミンCとビタミンEの合計量は、本発明の口腔内溶解錠全量に対して25〜60重量%、好ましくは30〜50重量%配合できる。
【0009】
本発明に用いるカルシウム成分は、天然あるいは合成のいずれであってもよい。天然物は貝殻カルシウム、牛骨紛、卵殻カルシウム、サンゴカルシウム、ドロマイト、乳清カルシウムなどがあげられ、また合成系のカルシウムとしては、グルコン酸カルシウム、乳酸カルシウム、リン酸カルシウム、グリセロリン酸カルシウム、パントテン酸カルシウム、クエン酸カルシウム、アスパラギン酸カルシウム等を例示できる。これらカルシウム成分は、本発明の口腔内溶解錠全量に対して30〜60重量%、好ましくは30〜50重量%配合することができる。
【0010】
本発明に用いる糖アルコールはパラチニット、マルチトール、ソルビトールから1種以上選択され、口腔内溶解錠全量に対して30〜60重量%、好ましくは40〜60重量%配合でき、製造段階や物流段階で欠け割れ等の摩損が無く、かつ口腔内で咀嚼、溶解させる際ざらつきの無い使用感に優れたものがえられる。さらにポリデキストロースや還元デキストリンやマルチトールやマルトトリイトール等を含む還元澱粉糖化物等の2糖以上の重合還元糖を口腔内溶解錠全量に対して1〜10重量%配合すると、より製造段階や物流段階で欠け割れ等の摩損が改善できる。
【0011】
本発明に用いる油溶性カンゾウ抽出物は、カンゾウ(植物名:グリチリザ・グラブラ、グリチリザ・インフラタ、グリチリザ・アラレアシス)カンゾウまたはその同属植物から有機溶媒(例えばメタノール、エタノール、アセトン、酢酸エチル、クロロホルムなど)を用いて抽出することにより製造できる。抽出には生、または乾燥したカンゾウ、及びその同属植物植物体のいずれを用いてもよく、またいずれの部位を用いることができるが、根部が好ましい。
【0012】
また、大豆イソフラボン抽出物は、マメ科(leguminosae)の植物であるダイズ(Glycine max Merrill)の種子、胚軸を原料として、例えば、特開昭62−126186号公報に記載された一般的な方法により配糖体として得ることができる。本発明では、公知の精製段階で酸加熱もしくはβ-グルクロニターゼ酵素を用いて加水分解する方法で、イソフラボン配糖体を加水分解したものが好ましい。
【0013】
茶抽出物は一般的に飲用される(Camellia sinensis)をはじめとする緑茶、ウーロン茶、紅茶、プアール茶等から選択可能であり、該抽出物は、エピガロカテキン類、エピカテキン類、ガロカテキン類を含有している。これら茶抽出物は、例えば特開昭64−90124号公報、特開平1−265023号公報に記載されている方法にて得られる。
【0014】
ぶどう種子抽出物は、ヨーロッパぶどう(Vitis vinifera)の種子を用い、プロアントシニジン、アントシアニジン類を含んでいる。例えば特公平06−31208号公報、特開昭63−162685号公報、特開平03−200781号公報、特開平02−48593号公報、特開平03−99090号公報等に記載されている方法にて得られ
【0015】
これら抽出物は、1種又は2種以上配合することができ、本発明の口腔内溶解錠全量に対して、抽出物乾燥重量として0.01〜5重量%、好ましくは0.05〜1重量%配合できる。
【0016】
本発明の口腔内溶解錠は、これら必須の成分に加えて、通常錠剤に配合でき、例えばクエン酸、リンゴ酸等の酸味剤、スクラロース、アスパルテーム、ステビア、アセサルファムK等の高甘味剤、蔗糖脂肪酸エステル、ステアリン酸マグネシウム等の滑沢剤、香料、ビタミンC及びビタミンEを除くビタミン類、亜鉛等のミネラル、及び抗酸化剤、歯垢形成抑制剤、口臭抑制剤などから適宜、本発明の効果を損なわない範囲で配合することができる。
【0017】
本発明の口腔内溶解錠の製造法を説明する。本発明では特に打錠方法を限定するものではないが、直接打錠する直打法では、十分な硬度、または硬度が得られても摩損性の低い錠剤は得られにくいので、予め、押し出し造粒、流動層造粒、混合攪拌造粒などの湿式造粒法により製造した顆粒を打錠する方法が好ましい。
【0018】
すなわち、ビタミン及び植物抽出物と糖アルコールとその他賦形剤を粉体混合し(用いる粉体は60メッシュ(通過する粒径が250μm以下))、アルコールや水、必要に応じて、さらにポリデキストロースや還元デキストリンやマルチトールやマルトトリイトール等の2糖以上の重合還元糖を単独あるいは組合せて粉体を湿潤させ造粒して顆粒とする。最後にこの顆粒に香料や滑沢剤あるいは熱や水分に弱い有用成分などを混合し打錠する。
【0019】
用いる打錠機としてはロータリー打錠機、単発打錠機のいずれを使用しても良いが量産性の観点からロータリー打錠機を用いることが好ましい。打錠機に用いる杵の大きさは、杵が円形である場合は直径12から20mm以下であることが好ましい。杵が三角形、四角形の場合1辺が約5から15mmの大きさが好ましい。尚円形の打錠品を得る場合、錠剤の厚みは4から7mmの範囲に調整され、1錠の重量は500から3000mgであり、その錠剤の硬度は木屋式硬度計にて直径方向で測定するとき、5〜15kg、特に7〜13kgであることが最も好ましい。5kgより低いと錠剤自身がもろく製造及び物流段階で摩損性が大きく、カルシウムなどの無機の粉体との組み合わせでは、特に粉っぽく感じ使用感に劣る。また15kg超えると咀嚼しにくくなり、又咀嚼した時の断片の舌ざわりのよさが充分にえられないので好ましくない。
【0020】
【実施例】
次に、実施例、比較例をあげて、本発明をさらに詳しく説明する。いうまでもなく、本発明はこれら実施例に限るものでなく、また特に断らない限り[%]は[重量%]を示す。
【0021】
以下の試験1、試験2、試験3に示す処方のうち、ポリデキストロース(製品名PO−40、東和化成工業社製)、香料及び蔗糖脂肪酸エステルを除く粉体を秤量し、流動層造粒にて、水もしくはポリデキストロースの50%溶液にてスプレーし造粒した。得られた顆粒に香料、蔗糖脂肪酸エステルを加え、アスコルビン酸を含む錠剤は直径20mm、1錠あたりの重量が1900mgとし、一定の打錠圧にて打錠した。尚、本試験ではビタミンE含量20%のビタミンE製剤を用いた。またカルシウム成分を含む錠剤は直径20mm、1錠あたりの重量が2000mgになるよう一定の打錠圧にて打錠した。
【0022】
得られた打錠品は、木屋式硬度計にて錠剤の直径方向の硬度を測定した。硬度は咀嚼時に硬くも無く咀嚼して断片化した場合であっても舌ざわりが良く、また製造時、物流時に欠け割れ等の摩損が生じない硬度として5から15kgの範囲を合格とした。摩損度試験は日本薬局方第14局収載予定の摩損度試験機(JP Forum Vol.6 No.4(1997)p14〜15記載)を用いて試験をおこなった。摩損度試験機のドラム内に20錠の錠剤を入れ、25回転/1分で10分間回転させた後摩損度(初期質量に対する減少質量の質量百分率)を求め摩損度が1%以下であれば合格とした。これら硬度と摩損度の両方に合格する範囲を総合して合格と判定した。結果を表1〜3に示す。
【0023】
【表1】

Figure 0004886107
【0024】
表1から明らかなように、植物抽出物やビタミンC、ビタミンEあるいはカルシウム成分を有効成分とし、糖アルコールを賦形剤として配合し常法にて製剤化したとき、同じ糖アルコールでもパラチニット、マルチトール、ソルビトールを使用した時にのみ適度な硬度でかつ使用感も良くさらに摩損性が低い優れた口腔内溶解錠が得られた。
【0025】
【表2】
Figure 0004886107
【0026】
また、表2から、ビタミンC、ビタミンEの配合量が増えるに従い硬度が出にくくなると同時に摩損度が増すことから、ビタミンCとビタミンEの総量は60重量%以下、糖アルコールの量は30重量%以上であることが好ましく、またポリデキストロースを使用することにより、さらに硬度が出やすくかつ摩損度が低下することが明らかになった。
【0027】
【表3】
Figure 0004886107
【0028】
試験3では貝殻カルシウムの配合量が増すと、硬度は変わらないものの、摩損度試験においては割れが生じ、製造時及び物流時の衝撃に耐えられないものとなった。よって試験1及び試験3より、カルシウム含有物を60重量%以下で、糖アルコールが30重量%以上配合することが好ましい。
【0029】
次いで、以下に示す実施例を製造し、同様に評価したところ適度な硬度でかつ使用感も良くさらに摩損性が低い優れた口腔内溶解錠であった。
Figure 0004886107
1錠2000mg、直径20mm円形錠剤を製造したところ、硬度13.5kg、摩損度0.4%で使用感も良好であった。
【0030】
Figure 0004886107
1錠1800mg、直径18mm円形錠剤を製造したところ、硬度11.5、摩損度0.4%で使用感も良好であった。
【0031】
Figure 0004886107
*ビタミンE製剤 天然ビタミンEとしてd−a、゜、?、d混合タイプ、総ビタミンEとして20%含有、その他添加剤としてアラビアガム、デキストリン等の粉末化基剤配合。スプレードライ品。
1錠1900mg、直径20mm円形錠剤を製造したところ、硬度11.3、摩損度0.7%で使用感も良好であった。
【0032】
Figure 0004886107
*β-カロチン ゜-カロチン1%含有その他アラビアガムデキストリンの粉末化基剤含む、スプレードライ品。*ビタミンE製剤dl-a-トコフェロールを無水珪酸に含浸させたもの。dl-aトコフェロールとして50%含有。1錠1700mg直径18mm円形錠剤を製造したところ、硬度14.0、摩損度0.7%で使用感も良好であった。
【0033】
【発明の効果】
本発明によれば、歯周病予防用の製剤として、ビタミンC及びビタミンEあるいはカルシウム成分とパラチニット、マルチトール、ソルビトールから選ばれる糖アルコールを組合せることによって、それら有効な成分の局所での有効性を高め、また口腔内溶解錠としての物性上の問題であった、欠け、割れ等の発生を解決し優れた使用感の口腔内溶解錠を提供できる。さらに油溶性カンゾウ抽出物、大豆イソフラボン抽出物、茶抽出物、ぶどう種子抽出物の1種もしくは2種以上からなる植物抽出物を配合することもできる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an orally dissolving tablet for the purpose of preventing periodontal disease.
[0002]
[Prior art]
Conventionally, natural products having various aspects such as antibacterial and anti-inflammatory effects have been proposed for the purpose of preventing periodontal disease. For example, JP-A-11-243910 discloses a combination of highly soluble calcium and an oil-soluble licorice extract, soy isoflavone, and an antibacterial plant extract composed of tea extract, and JP-A-11-302142 discloses vitamins C and E. The composition for periodontal disease prevention by the combination with natural polyphenol is disclosed. As a food dosage form containing such a composition, a tablet that is dissolved in the oral cavity is useful for expecting a local action in the oral cavity.
[0003]
In addition, orally-dissolving tablets should be moderately hard to chew and dissolve in the oral cavity, have no roughness when squeezed, and should not cause wear such as chipping or cracking in the manufacturing or distribution stages. . However, when vitamins and calcium components, which are active ingredients for preventing periodontal disease, are added and the amount is increased, depending on the type of sugar alcohol used in orally dissolving tablets, the hardness of the tablet may not be sufficient. It has been found that even if the hardness is high, the wear such as cracks and chipping is so great that it cannot withstand impacts in the manufacturing and distribution stages.
[0004]
[Problems to be solved by the invention]
The present invention provides an orally-dissolving tablet for the prevention of periodontal disease that has moderate hardness, low friability, has no roughness during mouth opening, and has an excellent usability.
[0005]
[Means for Solving the Problems]
The present inventor, as a result of diligent examination to improve the feeling of use such as melting in the mouth, without cracks, cracks, etc., in periodontal disease preventing oral dissolving tablets containing vitamin C and vitamin E or calcium components as active ingredients, Surprisingly, the above problem can be solved by a combination of certain sugar alcohols, and the present invention has been completed.
[0006]
That is, the present invention
Item 1: An oral-dissolving tablet for preventing periodontal disease, comprising vitamin C and vitamin E or calcium as active ingredients and at least one sugar alcohol selected from paratinite, maltitol, and sorbitol. .
Item 2 The oral-dissolving tablet for periodontal disease prevention according to Item 1, further comprising at least one selected from polymerized reducing sugars of two or more sugars.
Item 3 Any one of Items 1 and 2, wherein the total amount of vitamin C and vitamin E, or the amount of calcium component is 25 to 60% by weight, and the amount of sugar alcohol is 30 to 60% by weight Orally dissolving tablet for periodontal disease prevention according to paragraph.
Item 4. A tablet obtained by tableting granules prepared by wet granulation, wherein the tablet hardness is 5 kg to 15 kg, orally dissolving tablet for preventing periodontal disease according to any one of Items 1, 2, 3 .
Item 5 Furthermore, one, two or more selected from plant extracts consisting of oil-soluble licorice extract, soybean isoflavone extract, tea extract, and grape seed extract are blended. 5. The oral dissolving tablet for periodontal disease prevention of any one of 4.
In the present invention, “periodontal disease prevention” means to suppress and prevent the onset of periodontal disease so as not to become periodontal disease, to suppress and prevent the progression of periodontal disease and life It means reducing the risk of periodontal disease that affects the progression and onset of periodontal disease, depending on habits, systemic diseases or certain general conditions.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
Vitamin C used in the present invention includes ascorbic acid, sodium ascorbate, calcium ascorbate and the like, and can be blended in the composition at 25 to 60% by weight, preferably 25 to 40% by weight.
Vitamin E used in the present invention contains natural or synthetic vitamin E and vitamin E such as esters such as succinic acid, acetic acid and nicotinic acid in a composition of 0.1% by weight to 10% by weight, preferably 0.8%. 5% to 5% by weight can be blended.
[0008]
Vitamin E is most preferably used in the form of powdered vitamin E preparation. Powdered vitamin E preparation is, for example, a method in which vitamin E is emulsified with gum arabic or the like, and a powdered base such as dextrin or lactose is added and spray dried, or a method of adsorbing on porous powder such as silicon dioxide or dextrin Can be manufactured. The powdered vitamin E preparation contains 1 to 50% by weight of vitamin E, and 0.05 to 40% by weight can be blended in the composition as a vitamin E preparation. The total amount of vitamin C and vitamin E may be 25 to 60% by weight, preferably 30 to 50% by weight, based on the total amount of the oral dissolving tablet of the present invention.
[0009]
The calcium component used in the present invention may be either natural or synthetic. Natural products include shell calcium, beef bone powder, eggshell calcium, coral calcium, dolomite, and whey calcium. Synthetic calcium includes calcium gluconate, calcium lactate, calcium phosphate, calcium glycerophosphate, calcium pantothenate, Examples include calcium citrate and calcium aspartate. These calcium components can be blended in an amount of 30 to 60% by weight, preferably 30 to 50% by weight, based on the total amount of the orally dissolving tablet of the present invention.
[0010]
The sugar alcohol used in the present invention is selected from at least one of paratinite, maltitol, and sorbitol, and can be blended in an amount of 30 to 60% by weight, preferably 40 to 60% by weight, based on the total amount of the orally dissolving tablet. There is no wear such as chipping, and there is no roughness when chewing and dissolving in the oral cavity. Furthermore, when 1 to 10% by weight of a polymerized reducing sugar such as reduced starch saccharified product containing polydextrose, reduced dextrin, maltitol, maltotriitol and the like is added to 1 to 10% by weight based on the total amount of the oral dissolving tablet, It is possible to improve wear and tear such as cracks at the distribution stage.
[0011]
The oil-soluble licorice extract used in the present invention is an organic solvent (for example, methanol, ethanol, acetone, ethyl acetate, chloroform, etc.) It can manufacture by extracting using. For extraction, any of raw or dried licorice and its related plant bodies may be used, and any part can be used, but the root is preferred.
[0012]
The soy isoflavone extract is prepared by using a seed or hypocotyl of soybean (Glycine max Merrill) which is a leguminosae plant as a raw material, for example, a general method described in JP-A-62-126186. Can be obtained as a glycoside. In the present invention, a product obtained by hydrolyzing an isoflavone glycoside by a method of hydrolysis using acid heating or β-glucuronidase enzyme in a known purification step is preferred.
[0013]
The tea extract can be selected from green tea, oolong tea, black tea, puerh tea, etc., which are generally drunk (Camellia sinensis), and the extract contains epigallocatechins, epicatechins, gallocatechins Contains. These tea extracts can be obtained by the methods described in, for example, JP-A Nos. 64-90124 and 1-265023.
[0014]
The grape seed extract uses European grape (Vitis vinifera) seeds and contains proanthinidine and anthocyanidins. For example, the methods described in JP-B-06-31208, JP-A-63-162885, JP-A-03-200781, JP-A-02-48593, JP-A-03-99090, etc. Obtained [0015]
These extracts can be used alone or in combination of two or more, and 0.01 to 5% by weight, preferably 0.05 to 1% by weight as the dry weight of the extract with respect to the total amount of the oral dissolving tablet of the present invention. % Can be blended.
[0016]
In addition to these essential ingredients, the oral dissolving tablet of the present invention can be usually added to tablets, for example, sour agents such as citric acid and malic acid, high sweeteners such as sucralose, aspartame, stevia, acesulfame K, sucrose fatty acid Effects of the present invention are appropriately selected from lubricants such as esters and magnesium stearate, fragrances, vitamins other than vitamin C and vitamin E, minerals such as zinc, antioxidants, plaque formation inhibitors and halitosis inhibitors. It can mix | blend in the range which does not impair.
[0017]
The manufacturing method of the intraoral dissolution tablet of this invention is demonstrated. In the present invention, the tableting method is not particularly limited. However, in the direct compression method in which direct tableting is performed, a tablet with low wearability is hardly obtained even if sufficient hardness or hardness is obtained. A method of tableting a granule produced by a wet granulation method such as granulation, fluidized bed granulation or mixed stirring granulation is preferred.
[0018]
In other words, vitamins and plant extracts, sugar alcohols and other excipients are mixed in powder form (powder used is 60 mesh (particle size passing through is 250 μm or less)), alcohol and water, and if necessary, polydextrose Or a reduced dextrin, maltitol, maltotriitol, or other two or more polymerized reducing sugars, alone or in combination, wet the powder and granulate to form granules. Finally, the granules are mixed with a fragrance, a lubricant, or a useful component that is weak against heat and moisture, and tableted.
[0019]
As the tableting machine to be used, either a rotary tableting machine or a single-shot tableting machine may be used, but it is preferable to use a rotary tableting machine from the viewpoint of mass productivity. The size of the punch used in the tableting machine is preferably 12 to 20 mm in diameter when the punch is circular. When the ridge is a triangle or a quadrangle, one side is preferably about 5 to 15 mm. In the case of obtaining a round tableted product, the thickness of the tablet is adjusted in the range of 4 to 7 mm, the weight of one tablet is 500 to 3000 mg, and the hardness of the tablet is measured in the diameter direction with a Kiya-type hardness meter. Is most preferably 5 to 15 kg, particularly 7 to 13 kg. If it is lower than 5 kg, the tablet itself is brittle and has high friability in the production and distribution stages. On the other hand, if the weight exceeds 15 kg, it is difficult to chew, and the texture of the fragments when chewed cannot be sufficiently obtained, which is not preferable.
[0020]
【Example】
Next, the present invention will be described in more detail with reference to examples and comparative examples. Needless to say, the present invention is not limited to these examples, and unless otherwise specified, [%] indicates [% by weight].
[0021]
Among the formulations shown in Test 1, Test 2, and Test 3 below, powders excluding polydextrose (product name PO-40, manufactured by Towa Kasei Kogyo Co., Ltd.), fragrance, and sucrose fatty acid ester are weighed, and fluidized bed granulation is performed. Then, it was sprayed and granulated with a 50% solution of water or polydextrose. Fragrance and sucrose fatty acid ester were added to the obtained granules, and tablets containing ascorbic acid had a diameter of 20 mm and a weight per tablet of 1900 mg, and were compressed with a constant compression pressure. In this test, a vitamin E preparation having a vitamin E content of 20% was used. Tablets containing calcium components were tableted at a constant tableting pressure so that the diameter was 20 mm and the weight per tablet was 2000 mg.
[0022]
The resulting tableted product was measured for hardness in the diameter direction of the tablet with a Kiyama-type hardness meter. The hardness was not hard at the time of chewing, and even when it was chewed and fragmented, the texture was good, and the hardness in the range of 5 to 15 kg was accepted as a hardness that did not cause wear such as chipping cracks during production and distribution. The friability test was conducted using a friability tester (JP Forum Vol.6 No.4 (1997) p14-15 described) scheduled to be listed in the Japanese Pharmacopoeia No.14. After putting 20 tablets in the drum of the friability tester and rotating for 10 minutes at 25 rotations per minute, the friability (mass percentage of the reduced mass with respect to the initial mass) is determined and if the friability is 1% or less Passed. The range that passed both the hardness and the friability was determined to be acceptable. The results are shown in Tables 1-3.
[0023]
[Table 1]
Figure 0004886107
[0024]
As is clear from Table 1, when plant extract, vitamin C, vitamin E, or calcium component is used as an active ingredient and sugar alcohol is used as an excipient and formulated in a conventional manner, the same sugar alcohol can be used for paratinite, multi Only when toll or sorbitol was used, an excellent orally-dissolving tablet having an appropriate hardness, good usability and low friability was obtained.
[0025]
[Table 2]
Figure 0004886107
[0026]
Also, as Table 2 shows, as the blending amount of Vitamin C and Vitamin E increases, the hardness becomes harder and at the same time the friability increases. It has been found that the hardness is preferably at least%, and the use of polydextrose makes it easier to obtain hardness and lowers the friability.
[0027]
[Table 3]
Figure 0004886107
[0028]
In Test 3, when the amount of shell calcium was increased, the hardness did not change, but in the friability test, cracking occurred, and the product was unable to withstand impacts during production and distribution. Therefore, from Test 1 and Test 3, it is preferable to blend the calcium-containing material at 60% by weight or less and the sugar alcohol at 30% by weight or more.
[0029]
Subsequently, the following examples were produced and evaluated in the same manner. As a result, the tablet was an excellent orally-dissolving tablet having an appropriate hardness, good usability, and low friability.
Figure 0004886107
When one tablet of 2000 mg and a diameter of 20 mm was manufactured, the hardness was 13.5 kg, the friability was 0.4%, and the usability was also good.
[0030]
Figure 0004886107
When 1800 mg of a tablet and a 18 mm diameter circular tablet were produced, the hardness was 11.5, the friability was 0.4%, and the usability was also good.
[0031]
Figure 0004886107
* Vitamin E preparation Natural vitamin E contains da, °,?, D mixed types, 20% total vitamin E, and other additives such as gum arabic and dextrin. Spray-dried product.
When 1900 mg of 1 tablet and a 20 mm diameter circular tablet were manufactured, the hardness was 11.3, the friability was 0.7%, and the usability was also good.
[0032]
Figure 0004886107
* Beta-carotene-spray-dried product containing 1% carotene and other powdered base of gum arabic dextrin. * Vitamin E preparation dl-a-tocopherol impregnated with anhydrous silicic acid. Contains 50% as dl-a tocopherol. When 1 tablet 1700mg diameter 18mm diameter circular tablet was manufactured, the hardness was 14.0, the friability was 0.7%, and the usability was also good.
[0033]
【Effect of the invention】
According to the present invention, as a preparation for preventing periodontal disease, vitamin C and vitamin E or a calcium component and a sugar alcohol selected from palatinit, maltitol, and sorbitol are combined, and these effective components are locally effective. In addition, it is possible to provide an orally-dissolving tablet with an excellent feeling of use by solving the occurrence of chipping and cracking, which has been a problem in physical properties as an orally-dissolving tablet. Furthermore, the plant extract which consists of 1 type (s) or 2 or more types of an oil-soluble licorice extract, soybean isoflavone extract, tea extract, and grape seed extract can also be mix | blended.

Claims (2)

貝殻カルシウム成分を有効成分として32〜55重量%、且つパラチニット、マルチトール、ソルビトールからなる糖アルコールから選択される1種以上を32〜60重量%配合した湿式造粒により調製した顆粒を打錠した錠剤であって、その錠剤硬度が10.6kg〜13.5kgであることを特徴とする歯周病予防用口腔内溶解錠。Granules prepared by wet granulation containing 32 to 55 % by weight of a shell calcium component as an active ingredient and 32 to 60 % by weight of one or more sugar alcohols selected from paratinite, maltitol and sorbitol were tableted. An orally-dissolving tablet for preventing periodontal disease, which is a tablet and has a tablet hardness of 10.6 kg to 13.5 kg. さらに大豆イソフラボン抽出物を0.05〜1重量%配合することを特徴とする請求項1項に記載の歯周病予防用口腔内溶解錠。Furthermore, the soy isoflavone extract is mix | blended 0.05 to 1weight%, The oral dissolution tablet for periodontal disease prevention of Claim 1 characterized by the above-mentioned.
JP2000313711A 2000-10-13 2000-10-13 Oral dissolving tablets for periodontal disease prevention Expired - Fee Related JP4886107B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000313711A JP4886107B2 (en) 2000-10-13 2000-10-13 Oral dissolving tablets for periodontal disease prevention

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000313711A JP4886107B2 (en) 2000-10-13 2000-10-13 Oral dissolving tablets for periodontal disease prevention

Publications (2)

Publication Number Publication Date
JP2002121133A JP2002121133A (en) 2002-04-23
JP4886107B2 true JP4886107B2 (en) 2012-02-29

Family

ID=18793083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000313711A Expired - Fee Related JP4886107B2 (en) 2000-10-13 2000-10-13 Oral dissolving tablets for periodontal disease prevention

Country Status (1)

Country Link
JP (1) JP4886107B2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002121146A (en) * 2000-10-13 2002-04-23 Sunstar Inc Preparation for preventing periodontal disease
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
WO2005046702A1 (en) * 2003-09-19 2005-05-26 Sunstar Inc. Method of inhibiting alveolar resorption and peridental membrane loss and composition for internal use to be used therein
JP2005112852A (en) * 2003-09-19 2005-04-28 Sunstar Inc Internal medicinal composition for inhibiting gingival inflammation and periodontal membrane loss
CN1764448A (en) * 2004-03-26 2006-04-26 朝日啤酒株式会社 A protectant of periodontal membranes
US8168161B2 (en) * 2004-12-22 2012-05-01 Hill's Pet Nutrition, Inc. Method to promote oral health in companion animals
EP2591774B1 (en) 2010-07-09 2020-05-27 Teijin Pharma Limited Orally disintegrating tablet
EP3236951B1 (en) * 2014-12-22 2018-11-21 Lacer, S.A. Oral dissolvable pharmaceutical dosage form for the treatment of oral diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE850810A (en) * 1976-01-30 1977-05-16 Indiana University Foundation NON-CARIOGENIC EDIBLE PRODUCT
JPS62273910A (en) * 1986-05-23 1987-11-28 Shino Junko Composition for oral cavity
EP0343703A3 (en) * 1988-05-26 1990-06-06 The Procter & Gamble Company Mineral supplements with sugar alcohols
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5204115A (en) * 1990-12-12 1993-04-20 Suomen Xyrofin Oy Directly compressible xylitol and method
JP3207912B2 (en) * 1991-03-15 2001-09-10 カネボウ株式会社 Collagenase activity inhibitor
JPH04364127A (en) * 1991-06-10 1992-12-16 Tooa Eiyoo Kk Medicinal preparation containing cycloheptenopyridine derivative or its salt and its preparation
EP0553777B1 (en) * 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
JP3119801B2 (en) * 1995-09-28 2000-12-25 武田薬品工業株式会社 Method for stabilizing a vitamin-containing composition
JPH09194381A (en) * 1996-01-17 1997-07-29 Kowa Co Chewable tablet containing calcium salt
JPH09295924A (en) * 1996-04-30 1997-11-18 Lion Corp Acid neutralizing agent for dental plaque and composition for oral cavity
JP4098376B2 (en) * 1996-09-05 2008-06-11 ビーエーエスエフ ソシエタス・ヨーロピア Water-soluble vitamin composition having excellent tablet characteristics and method for producing the same
JPH1087502A (en) * 1996-09-10 1998-04-07 Sunstar Inc Composition for oral cavity
JPH10298073A (en) * 1997-04-28 1998-11-10 Sekisui Chem Co Ltd Therapeutic agent for inflammatory stomatopathy
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
JPH11137208A (en) * 1997-11-14 1999-05-25 Nikken Chem Co Ltd Solid material rapidly soluble in oral cavity and its production
JP3648587B2 (en) * 1998-03-04 2005-05-18 サンスター株式会社 Periodontal disease prevention or periodontal disease progression food composition
JPH11269067A (en) * 1998-03-20 1999-10-05 Eisai Co Ltd Quickly collapsing tablet containing vitamin e and c
JP2000007555A (en) * 1998-04-23 2000-01-11 Nitto Yakuhin Kogyo Kk Tablet and its production
JP3763075B2 (en) * 1998-04-24 2006-04-05 サンスター株式会社 Food composition, oral composition and pharmaceutical composition for prevention or treatment of periodontal disease
GB9825033D0 (en) * 1998-11-13 1999-01-13 Nycomed Pharma As Process
JP2002121146A (en) * 2000-10-13 2002-04-23 Sunstar Inc Preparation for preventing periodontal disease

Also Published As

Publication number Publication date
JP2002121133A (en) 2002-04-23

Similar Documents

Publication Publication Date Title
CN111432840B (en) Solid oral nicotine formulation
CA2196150C (en) Process for the preparation of medicated chewing gum provided with a pleasant taste independent from the active agent incorporated therein
JP4947833B2 (en) Process for producing granules suitable for the production of fast disintegrating oral dissolving tablets
US6358526B1 (en) Method of making tablets and tablet compositions produced therefrom
KR101351674B1 (en) Novel compositions containing polyphenols
US20090169682A1 (en) Functional Masticatory Material, Method Of Producing The Same And Method Of Using The Same
KR101386022B1 (en) Quickly disintegrating tablet produced by direct dry-tabletting
JPH0948726A (en) Rapidly disintegrating preparation in mouth cavity and its production
US20130302387A1 (en) Compositions and Formulations for the Treatment of Halitosis
CN111447921B (en) Nicotine tablet
CA2440713A1 (en) Nicotine-containing oral dosage form
JP3648587B2 (en) Periodontal disease prevention or periodontal disease progression food composition
JP2007131620A (en) Functional masticatory material, method for producing the same and use thereof
TWI556823B (en) Orally disintegrating tablet containing acarbose
JP4886107B2 (en) Oral dissolving tablets for periodontal disease prevention
US4882161A (en) Chewable, non-gritty calcium citrate tablet
WO2007020830A1 (en) Oral composition
JP4565219B2 (en) Polyphenol-containing granule or polyphenol-containing chewable tablet and method for producing the same
JP6092672B2 (en) Orally rapidly disintegrating tablets
JP2007246541A (en) Functional masticatory material and method for producing the same
WO2006072920A2 (en) Tablets of stevia extract and process for their preparation
US11911375B2 (en) Solid oral nicotine formulation
JP2013209332A (en) Method for producing solid preparation having reduced unpleasant taste
WO2010067151A1 (en) Quick disintegrating taste masked composition
JP4630614B2 (en) Fast disintegrating solid preparation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100323

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111206

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111209

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141216

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees